Angiotensin‐converting enzyme 2 deficiency accelerates and angiotensin 1‐7 restores age‐related muscle weakness in mice

• Egile Nagusiak: Hikari Takeshita (Egilea), Koichi Yamamoto (Egilea), Satoko Nozato (Egilea), Masao Takeda (Egilea), So‐ichiro Fukada (Egilea), Tadakatsu Inagaki (Egilea), Hirotsugu Tsuchimochi (Egilea), Mikiyasu Shirai (Egilea), Yoichi Nozato (Egilea), Taku Fujimoto (Egilea), Yuki Imaizumi (Egilea), Serina Yokoyama (Egilea), Motonori Nagasawa (Egilea), Go Hamano (Egilea), Kazuhiro Hongyo (Egilea), Tatsuo Kawai (Egilea), Hiroko Hanasaki‐Yamamoto (Egilea), Shuko Takeda (Egilea), Toshimasa Takahashi (Egilea), Hiroshi Akasaka (Egilea), Norihisa Itoh (Egilea), Yoichi Takami (Egilea), Yasushi Takeya (Egilea), Ken Sugimoto (Egilea), Hironori Nakagami (Egilea), Hiromi Rakugi (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2018-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background A pharmacologic strategy for age‐related muscle weakness is desired to improve mortality and disability in the elderly. Angiotensin‐converting enzyme 2 (ACE2) cleaves angiotensin II into angiotensin 1‐7, a peptide known to protect against acute and chronic skeletal muscle injury...